AI assistant
Moderna, Inc. — Director's Dealing 2020
Nov 24, 2020
30610_dirs_2020-11-24_c1a9f5da-9a7c-4f49-8d0c-12260440adbd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-11-23
Reporting Person: Zaks Tal Zvi (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-11-23 | Common Stock | M | 5000 | $12.21 | Acquired | 5000 | Direct |
| 2020-11-23 | Common Stock | M | 10000 | $19.15 | Acquired | 15000 | Direct |
| 2020-11-23 | Common Stock | S | 1440 | $99.31 | Disposed | 13560 | Direct |
| 2020-11-23 | Common Stock | S | 6836 | $100.12 | Disposed | 6724 | Direct |
| 2020-11-23 | Common Stock | S | 6724 | $101.21 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-11-23 | Stock Option (Right to Buy) | $12.21 | M | 5000 | Disposed | 2027-02-23 | Common Stock (5000) | Direct |
| 2020-11-23 | Stock Option (Right to Buy) | $19.15 | M | 10000 | Disposed | 2026-08-10 | Common Stock (10000) | Direct |
Footnotes
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.70 to $99.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.72 to $100.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.78 to $101.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.
F6: This option is fully vested and exercisable.